Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe fibrosis should be treated according to international NAFLD guidelines. Currently, regulatory agencies have not approved any pharmaceutical treatment for NAFLD. Vitamin E and pioglitazone are efficacious for NASH resolution; however, their benefits must be weighed against the reported risks. In a phase 2 trial, a glucagon-like peptide-1 agonist commonly used for diabetes and obesity was found to improve liver histology in patients with NASH. Furthermore, therapeutic agents targeting NASH pathogenesis, including bile acid signaling, insulin resistance, and lipid metabolism, are in various phases of clinical development. In this article, we review the benefits and drawbacks of current pharmacotherapy and the efficacy of upcoming treatments for NASH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical and molecular hepatology - 29(2023), Suppl vom: 20. Feb., Seite S268-S275 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
An, Jihyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| Anmerkungen: |
Date Completed 15.03.2023 Date Revised 23.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3350/cmh.2022.0437 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350488037 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350488037 | ||
| 003 | DE-627 | ||
| 005 | 20231226045120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3350/cmh.2022.0437 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350488037 | ||
| 035 | |a (NLM)36537018 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a An, Jihyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological advances in the treatment of nonalcoholic fatty liver diseases |b focused on global results of randomized controlled trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2023 | ||
| 500 | |a Date Revised 23.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe fibrosis should be treated according to international NAFLD guidelines. Currently, regulatory agencies have not approved any pharmaceutical treatment for NAFLD. Vitamin E and pioglitazone are efficacious for NASH resolution; however, their benefits must be weighed against the reported risks. In a phase 2 trial, a glucagon-like peptide-1 agonist commonly used for diabetes and obesity was found to improve liver histology in patients with NASH. Furthermore, therapeutic agents targeting NASH pathogenesis, including bile acid signaling, insulin resistance, and lipid metabolism, are in various phases of clinical development. In this article, we review the benefits and drawbacks of current pharmacotherapy and the efficacy of upcoming treatments for NASH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Nonalcoholic fatty liver disease | |
| 650 | 4 | |a Nonalcoholic steatohepatitis | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Pioglitazone |2 NLM | |
| 650 | 7 | |a X4OV71U42S |2 NLM | |
| 700 | 1 | |a Sohn, Joo Hyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and molecular hepatology |d 2012 |g 29(2023), Suppl vom: 20. Feb., Seite S268-S275 |w (DE-627)NLM220236712 |x 2287-285X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:Suppl |g day:20 |g month:02 |g pages:S268-S275 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3350/cmh.2022.0437 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e Suppl |b 20 |c 02 |h S268-S275 | ||